Inflammatory and pro-fibrotic mediators

Inflammatory and pro-fibrotic mediators represent a broad and diverse class of signaling molecules, including cytokines (e.g., TNF-alpha, IL-6), chemokines, and growth factors (e.g., TGF-beta, PDGF), that regulate the body's response to tissue injury and chronic stress [1, 2, 3]. These molecules act in a complex network to recruit immune cells, promote cell proliferation, and stimulate the production of extracellular matrix components like collagen [4]. While essential for normal wound healing, the persistent or dysregulated expression of these mediators is a hallmark of chronic inflammatory diseases and progressive fibrosis in organs such as the lungs, liver, and kidneys [1, 4]. Key examples include Tumor Necrosis Factor alpha (TNF-alpha), which drives acute inflammation, and Transforming Growth Factor beta (TGF-beta), which is considered the master regulator of the fibrotic response [1, 2]. Therapeutic intervention typically involves targeting specific high-impact mediators or their receptors using monoclonal antibodies or small molecule inhibitors to mitigate tissue damage and prevent organ failure [5]. Drugs like Infliximab target TNF-alpha to treat autoimmune conditions, while Nintedanib inhibits multiple growth factor receptors to slow the progression of idiopathic pulmonary fibrosis [5]. Because this term describes a functional category rather than a single molecular entity, it is considered a collective grouping of multiple distinct therapeutic targets rather than a single receptor or enzyme.

Other names

Pro-inflammatory and fibrogenic factorsInflammatory cytokines and growth factorsMediators of inflammation and fibrosis

Neutralization of circulating cytokines, blockade of cell-surface receptors, or inhibition of downstream intracellular signaling kinases to attenuate inflammatory and fibrotic cascades.